Clinical Trial Update: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

This report presents long-term safety and efficacy findings for ABP 501, a biosimilar to adalimumab, in adults with moderate to severe rheumatoid arthritis from…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABP 501 (adalimumab biosimilar)

Snippet

Sponsor: Amgen | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2017-04-24